Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.09
+0.51006.73%
Post-market: 8.110.0209+0.26%19:58 EDT
Volume:7.21M
Turnover:58.70M
Market Cap:837.99M
PE:-1.55
High:8.40
Open:7.79
Low:7.75
Close:7.58
Loading ...

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

MT Newswires Live
·
05 Mar

Intellia Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
05 Mar

Intellia Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $30

THOMSON REUTERS
·
05 Mar

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Mar

Intellia Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
05 Mar

Stock Track | Intellia Therapeutics Plummets 5.05% as Analyst Cuts Price Target

Stock Track
·
04 Mar

Intellia Therapeutics: Promising Potential in Biotech with NTLA-2002 Advancements and Strategic Focus

TIPRANKS
·
04 Mar

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

MT Newswires Live
·
04 Mar

Intellia Therapeutics price target lowered to $50 from $90 at Truist

TIPRANKS
·
04 Mar

Bank of America Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
02 Mar

Intellia Therapeutics’ Promising Future: Buy Rating Backed by Strong Financials and Program Advancements

TIPRANKS
·
02 Mar

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Zacks
·
01 Mar

Stock Track | Intellia Therapeutics Plunges 5.8% Premarket on JPMorgan Downgrade and Competitive Concerns

Stock Track
·
28 Feb

Stock Track | Intellia Therapeutics Plunges 5% Premarket on JPMorgan Downgrade and Competitive Concerns

Stock Track
·
28 Feb

Intellia Therapeutics price target lowered to $37 from $47 at RBC Capital

TIPRANKS
·
28 Feb

Morgan Stanley Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
28 Feb

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

MT Newswires Live
·
28 Feb

Intellia Therapeutics Cut to Neutral From Overweight by JP Morgan

Dow Jones
·
28 Feb

Wells Fargo Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb